Nasopharyngeal- Respiratory Pathogen Panel with COVID-19, PCR (Filmarray)

Test Code
FARV2


Alias/See Also
Epic: LAB15532


Includes
Adenovirus, Coronavirus 229E, Coronavirus HKU1, Coronavirus NL63, Coronavirus OC43, SARS-CoV-2, Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A, Influenza B, Parainfluenza, Respiratory Syncytial Virus, Bordetella pertussis, Bordetella parapertussis, Chlamydohila pneumoniae, Mycoplasma pneumoniae


Preferred Specimen

 



Specimen Type: Swab
Source: Nasopharyngeal
Collection Container: Viral transport media (VTM)
Specimen Volume: Swab




Minimum Volume
0.3 mL


Other Acceptable Specimens

Specimen Type: Bronchoalveolar lavage (BAL)
Collection Container: Sterile container




Instructions
Nasopharyngeal Swab
  1. Collect according to standard technique and immediately place swab into 3ml Viral transport media (VTM) or Universal transport media (UTM). 
Bronchoalveolar lavage (BAL)
  1. Submit in sterile container.
  2. Minimum sample volume is 0.3 mL.
  3. BAL specimens should be processed and tested as soon as possible and must be received within 24 hours.
  4. Store/ship refrigerated.


Specimen Stability

Nasopharyngeal 
Room temperature: 4 hours
Refrigerated: 2 days
Frozen: Unacceptable

Bronchoalveolar lavage (BAL)
Room temperature: Unacceptable
Refrigerated: 24 hours
Frozen: Unacceptable




Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)

Specimen not received in appropriate transport container or at appropriate temperature.




Methodology

Real-time, nested multiplexed polymerase chain reaction using the BioFire Respiratory Panel 2.1 (RP2.1)



Setup Schedule

Daily




Report Available

1-2 days




Limitations

This assay cannot differentiate between Rhinovirus/Enterovirus. If necessary for patient care, a positive result for Rhinovirus/Enterovirus may be followed-up using an alternate method. This assay should not be used if B. pertussis infection is specifically suspected as it is less sensitive than other alternatives. If suspected, ensure that B. pertussis specific testing is ordered. Recent administration of a nasal influenza vaccine may cause false positive results for Influenza A and/or Influenza B.
Viral and bacterial nucleic acids may persist even though no viable organism is present. Detection of nucleic acid does not imply that the corresponding organisms are infectious or are the causative agents of clinical symptoms. A negative result does not exclude the possibility of viral or bacterial infection and should not be used as the sole basis for patient management decisions. Assay performance characteristics may vary with circulating strains and this assay may not be able to distinguish between existing viral strains and new variants as they emerge. Invalid results may be due to inhibiting substances in the specimen and recollection should occur.




Reference Range
See laboratory report


Performing Laboratory

Inova Laboratories

2832 Juniper Street

Fairfax, VA 22031




Last Updated: April 12, 2023
Last Review: N. Wolford, April 12, 2023


The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.